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Abstract
Introduction Since health insurance is compulsory in the
Netherlands, the centrally registered medical claims data
might pose a unique opportunity to evaluate quality of (car-
diac) care on a national level without additional collection
of data. However, validation of these claims data has not
yet been assessed.
Design Retrospective cohort study.
Methods National claims data (‘national registry’) were
compared with data collected by patient records reviews
in four representative hospitals (‘validation registry’). In
both registries, we extracted the national diagnosis codes
for ST-segment elevation myocardial infarction and non-
ST-segment elevation myocardial infarction of 2012 and
2013. Additionally, data on medication use at one year after
acute myocardial infarction (AMI) was extracted from the
Dutch pharmacy information systems and also validated
by local patient records reviews. The data were compared
at three stages: 1) validation of diagnosis and treatment
coding; 2) validation of the hospital where follow-up has
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taken place; 3) validation of follow-up medical treatment
after 365 days.
Results In total, 3,980 patients (‘national registry’) and
4,014 patients (‘validation registry’) were compared at
baseline. After one-year follow-up, 2,776 and 2,701 pa-
tients, respectively, were evaluated. Baseline characteristics,
diagnosis and individual medication were comparable be-
tween the two registries. Of all 52,672 AMI patients in the
Netherlands in 2012 and 2013, 81% used aspirin, 76% used
P2Y12 inhibitors, 85% used statins, 82% used beta-block-
ers and 74% angiotensin converting enzyme inhibitors/
angiotensin II antagonists. Optimal medical treatment was
achieved in 49% of the patients with AMI.
Conclusion Nationwide routinely collected claims data in
patients with an acute myocardial infarction are highly ac-
curate. This offers an opportunity for use in quality assess-
ments of cardiac care.
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Introduction
Acute myocardial infarction (AMI) is the most frequent
cause of death in the western world [1]. Numerous stud-
ies have shown the beneficial effects of medication follow-
ing AMI, resulting in increased survival [2–7]. In mod-
ern medicine the assessment of quality of care has become
increasingly important, especially measurements focussing
on patient-relevant outcomes such as mortality and patient
experience [8]. Health care professionals have a responsi-
bility to monitor their performances and share these results.
However, registration of clinical parameters is laborious and
time-consuming, which results in less time for actual patient
care [9].
Internationally, claims and clinical databases are ex-
plored as a source for quality assessments [10, 11]. The
added value of claims databases is the automatic data col-
lection on an ongoing basis, allowing us to follow patients
over a longer period of time and cover large populations
[12–14]. However, nationwide coverage is scarce. The
centrally registered claims data of health care companies
in the Netherlands might pose a unique opportunity to
evaluate quality of cardiac care on a national level. As all
inhabitants of the Netherlands are obliged to have health
insurance, almost all inhabitants (99.8%) are registered in
a central database (excluding military personnel and pris-
oners). However, the validity of these claims data has not
been assessed.
In the current study, national claims data will be vali-
dated for their use in the assessment of quality of care on
a national scale. For the validation of claims data, medical
treatment in the first year following AMI will be assessed
as a first quality indicator.
Methods
Validation method
To assess validity of national claims data, four representa-
tive hospitals are assessed by comparing claims data of each
hospital (‘national registry’) to local data, which is obtained
by local patient record reviews (‘validation registry’).
National registry
In the Netherlands, all reimbursements of the Dutch hospi-
tals are processed by insurance companies and registered by
a national diagnosis coding system. These are centrally reg-
istered and collected in the Dutch hospital information sys-
tems. Furthermore, information on prescribed medication
was extracted from the Dutch pharmacy information sys-
tems. For the current analysis, we selected all patients ad-
mitted in 2012 and 2013 for ST-segment elevation myocar-
dial infarction (STEMI) (coded as 0320.11.204) or non-ST-
segment elevation myocardial infarction (NSTEMI) (coded
as 0320.11.205). The age, gender and initial treatment (ei-
ther percutaneous coronary intervention (PCI) or no PCI)
of all patients were registered.
The hospital where the first follow-up code was reg-
istered was considered the hospital where follow-up had
taken place and therefore responsible for medical treat-
ment. If no follow-up code was registered, patients with
a PCI were allocated to the centre in which the PCI was
performed and patients without a PCI were allocated to the
hospital with the first STEMI or NSTEMI code.
For one year following the index event, mortality and
the use of the following medication was noted: aspirin
(acetylsalicylic acid and carbasalate calcium), P2Y12 in-
hibitor, statin, beta-blocker, angiotensin converting enzyme
(ACE) inhibitor or angiotensin II antagonist (AT2 antago-
nist). Optimal medical treatment was defined as the usage
of these five types of medication. Furthermore, the use of
a vitamin K antagonist (VKA) or novel oral anticoagulant
(NOAC) was noted as a potential cause for non-usage of
aspirin.
Medication use
Medication use was defined by the registered anatomical
therapeutic chemical (ATC) code and the defined daily dose
(DDD). The DDD is the assumed average maintenance dose
per day for a drug used for its main indication in adults,
composed by the World Health Organisation Collaborating
Centre for Drug Statistics Methodology [15]. It is a unit
of measurement and does not necessarily reflect the rec-
ommended or prescribed daily dose. The complete list of
the DDD per medication is shown in Table 1. The use of
pharmacy records has been validated in previous studies
[16].
National cohort
We assessed baseline data and pharmacological treatment
after one-year follow-up of all patients with AMI in the
Netherlands in 2012 and 2013.
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Table 1 Definition of medication use after 365 days
Medication ATC Code DDD 365 days
Aspirin B01AC06 (acetylsalicylic acid) or B01AC08 (carbasalate calcium) 180 DDD
P2Y12 inhibitor B01AC04 (clopidogrel), B01AC22 (prasugrel) and B01AC24 (ticagrelor) 180 DDD
Statin C10AAxx (all HMG CoA reductase inhibitors) 180 DDD
Beta-blocker C07xxxx (all beta-blocking agents and combinations) 45 DDD
ACE inhibitor/AT2 antagonist C09A, C09B and C09C (including combinations) 120 DDD
Vitamin K antagonist B01AA04 (phenprocoumon) and B01AA07 (acenocoumarol) 60 DDD
Novel oral anticoagulant B01AE07(dabigatran etexilate), B01AF01 (rivaroxaban) and B01AF02 (apix-
aban)
180 DDD
ACE angiotensin converting enzyme, AT2 angiotensin II ATC anatomical therapeutic chemical, DDD defined daily dose
HMG CoA hydroxymethyl-glutaryl coenzyme
To increase the algorithm’s sensitivity for detecting medication usage, a threshold of 45 to 180 DDD was used
Fig. 1 Data from the national
registry and validation registry
databases are compared at three
stages
National registry: Unique national diagnosis codes retrieved 
from the national database.
Validation registry: Unique national diagnosis codes 1
2
3
All patients with a follow-up in one of the four selected 
hospitals.
All patients available for follow-up after 365 days.
Validation of diagnosis and 
treatment
Validation of where follow-
up has taken place
Validation of 
pharmacological treatment
Primary diagnosis in neighbouring
hospital, follow-up in validation hospital.
Exclusion: Follow-up in other 
hospital than validation 
Exclusion: patients who died 
within one year.
Validation registry
In the four selected hospitals (an academic PCI centre, two
peripheral PCI centres and a non-PCI centre), all variables
extracted from the national claims database were collected
for validation through patient records reviews. Patients with
foreign health insurance were excluded, since these patients
were not included in the national analysis. The data from
the national registry and validation registry databases were
compared at three stages (Fig. 1).
1) Validation of diagnosis and treatment coding at first
admission
In every hospital, the patient population was selected by
using the hospital’s local claims registration database to
find all admitted patients with similar national diagnosis
codes for STEMI and NSTEMI. In patients with multiple
diagnosis codes within the study period, the first admission
code was used for the analysis. All codes were checked for
the final diagnosis at discharge in which STEMI is defined
as ST-elevation in ≥2 contiguous leads with ≥0.1mV in all
leads other than leads V2–V3 and a typical rise and/or fall
of cardiac biomarkers [17]. NSTEMI diagnosis is defined
by clinical symptoms suggestive for acute ischaemia, with
or without ST-segment depression or T-wave and presence
of cardiac biomarkers [18].
2) Validation of the hospital where follow-up has taken
place
In the validation hospitals, all patient records were screened
to assess where follow-up was performed. Patients whose
follow-up was performed in another hospital were excluded
from follow-up analyses. Additionally, in the non-PCI cen-
tre, patients could have been referred from another hospital
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Table 2 Patient characteristics
National registry Validation registry Difference National cohort
N = 3980 N = 4014 N = 59,534
Age (yrs) 66 ± 13 66 ± 13 67 ± 13
Male gender 2726 (68%) 2756 (69%) 1% 39,545 (66%)
Deceased <180 days 313 (8%) 292 (7%) 1% 5471 (9%)
Deceased <365 days 388 (10%) 346 (9%) 1% 6862 (12%)
Final diagnosis
STEMI 2028 (51%) 2048 (51%) 0% 25,768 (43%)
NSTEMI 1952 (49%) 1966 (49%) 0% 33,766 (57%)
Treated with PCI 2700 (68%) 2754 (69%) 1% 31,632 (53%)
STEMI ST-segment elevation myocardial infarction, NSTEMI non-ST-segment elevation myocardial infarction, PCI percutaneous coronary
intervention
where the initial AMI was registered, in which case these
patients were included for follow-up analysis. Finally, all
patients deceased within one year after their first admission
were excluded from the follow-up population, similar to the
national database, since one-year medication use could not
be assessed.
3) Validation of pharmacological treatment during one-
year follow-up
All remaining patient records were reviewed for medication
use.
Statistical analysis
The data are compared as absolute numbers and as a pro-
portion of the total population. A 95% confidence interval
(CI) was calculated with a population proportion formula
and indirect comparisons were made by chi-square test be-
tween the national registry and validation registry. A p-
value above 0.05 was considered comparable. Furthermore,
a direct comparison of the diagnosis coding in the local
database with the final diagnosis at discharge was made.
Results
1) Validation of diagnosis and treatment
Of all 59,534 admissions for AMI in the Netherlands in
2012 and 2013, 3,980 (7%) patients were registered in
one of the four validation hospitals according to the claim
database. Half of the diagnosis codes were for STEMI
(51%) (95% CI 49–53%), 68% (95% CI 67–70%) was
treated with PCI, mean age was 66 ± 13 years and 68%
(95% CI 67–70%) were male.
With patient records reviews in the four hospitals, 4,014
patients were identified. Similar to the national registry,
51% of the patients had a STEMI code (95% CI 49–53%),
69% (95% CI 67–70%) was treated with PCI, mean age
was 66 ± 13 and 69% (95% CI 67–70%) were male (Ta-
ble 2). For the direct validation of the diagnosis codes, the
final diagnosis at discharge was correlated with the first di-
agnosis coding. Due to transfers after treatment, a reliable
judgement for final diagnosis was not possible in 254 (6%)
patients. Of all remaining 1,977 STEMI codes, 88% was
coded correctly as STEMI. Of all 1,738 NSTEMI codes,
93% was coded correctly as NSTEMI.
2) Validation of the hospital where follow-up has taken
place
To validate the national algorithm of the location where fol-
low-up had taken place, all patients with outpatient follow-
up in another centre were excluded. In the national registry,
3,106 patients had their first follow-up code after their AMI
was registered in one of the four selected hospitals. Three
hundred and thirty patients died within one year and were
excluded, resulting in a follow-up population of 2,776 pa-
tients.
In the validation registry of 4,014 patients, 1,157 pa-
tients received follow-up in another hospital, 146 patients
were followed in one of the hospitals although the first ad-
mission of AMI was registered elsewhere, and 302 patients
died during the first year, resulting in a validated follow-up
population of 2,701 patients.
3) Validation of pharmacological treatment
Analysis of 2,776 patients in the national registry showed
aspirin use of 81% (95% CI 79–82%), P2Y12 inhibitor
use of 80% (95% CI 78–81%), statin use of 91% (95% CI
90–92%), beta-blocker use of 86% (95% CI 85–87%), ACE
inhibitor/AT2 antagonist use of 80% (95% CI 78–81%),
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Table 3 Pharmacological treatment during one year follow-up
National registry Validation registry Difference National cohort
N = 2776 N = 2701 N = 52,672
Patients with data available N = 1986
Aspirin 2246 (81%) 1689 (85%) 4%* 42,717 (81%)
P2Y12 inhibitor 2207 (80%) 1565 (79%) 1% 39,990 (76%)
Statin 2525 (91%) 1847 (93%) 2% 44,548 (85%)
Beta-blocker 2386 (86%) 1607 (81%) 5%* 43,189 (82%)
ACE inhibitor/AT2 antagonist 2213 (80%) 1656 (83%) 3% 38,795 (74%)
Vitamin K antagonist 465 (17%) 293 (15%) 2% 8669 (16%)
Novel oral anticoagulant 14 (1%) 13 (1%) 0% 184 (0%)
Optimal medical treatment 1665 (60%) 1087 (55%) 5%* 25,615 (49%)
With aspirin 1439 (52%) 959 (48%) 4% 22,311 (42%)
With VKA or NOAC 226 (8%) 128 (6%) 2% 3304 (6%)
At least 4 out of 5 2217 (80%) 1589 (80%) 0% 38,795 (74%)
At least 3 out of 5 2545 (92%) 1863 (94%) 2% 46,885 (89%)
ACE inhibitor Angiotensin converting enzyme inhibitor, AT2 antagonist angiotensin II antagonist, VKA vitamin K antagonist, NOAC novel oral
anticoagulant
Optimal medical treatment is defined as the use of a combination of aspirin-specie and/or vitamin K antagonist or novel oral anticoagulant,
P2Y12 inhibitor, statin, beta-blocker and ACE inhibitor. The replacement of VKA or NOAC is not included in the combined measurements in
which patients use at least three or four out of five medications
*P-value >0.05 for comparison between the national registry and validation registry
VKA use of 17% (95% CI 15–18%) and NOAC use of 1%
(95% CI 0–1%) (Table 3).
In the validation registry, one-year medication data were
available in 1,986 patients, showing comparable rates be-
tween the two registries (Table 3).
National cohort
Of all 59,534 patients (mean age 67 ± 13 years, 66% male),
6,862 (12%) patients died during one-year follow-up (Ta-
ble 2). Analysis of the remaining 52,672 patients showed
aspirin use of 81%, P2Y12 inhibitor use of 76%, statin use
of 85%, beta-blocker use of 82%, ACE inhibitor/AT2 an-
tagonist use of 73% (Table 3).
Discussion
In this study on validation of claims data, the findings can
be summarised as follows: (i) the two registries show com-
parable results for PCI treatment, diagnosis and medical
treatment in AMI patients, making it possible to use claims
data for quality assessments on a national scale; (ii) medi-
cal adherence one year after AMI in the Netherlands is at
an acceptable level.
Claims data and quality assessment
With the growing importance of quality assessment and ef-
ficient data collection, routinely collected claims data are
being used and studied more frequently for cardiac outcome
measurements. Benefits of claims databases are the auto-
matic and continuous data acquisition which make it less
laborious for health care professionals to gather health care
outcome measurements. Claims data have the advantage
of nationwide coverage, depend less on voluntary hospital
participation and can be used for chain of care evaluation,
including a connection with external datasets. However,
claims data are collected predominantly for billing pur-
poses, not for research. Therefore, it requires validation of
data accuracy. Data accuracy is particularly important when
using claims data as a quality indicator and when compar-
ing medical centres. As previously shown in the United
Kingdom, the current study demonstrates a sufficient accu-
racy of nationwide-used diagnostic, procedural and medi-
cal treatment codes with chart review [19]. Other studies
on comparisons of claims data with clinical registries show
various results [20–22]. This is due to differences in medi-
cal specialisation, study purpose and database quality. This
analysis composes a large sample size (7% of all Dutch
AMI patients) and data quality is verified in various stages.
Altogether, the use of these nationwide claims data offer
an efficient approach in quality measurement on a national
scale. However, claims data contain limited detailed clinical
information, which must be taken into account. Adjustment
for patient characteristics and case mix is possible up to
a certain level, but requires additional evaluation [22, 23].
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Medication compliance following myocardial infarction
Several large trials have shown the beneficial effects of
medication on patient outcome [2–7]. Therefore, medica-
tion poses a robust indicator for quality of care following
AMI [24].
Previous studies focussing on medication at discharge
show a substantial guideline adherence in patients with
AMI (65–69% were prescribed all five indicated drugs)
[25, 26]. Additionally, a recent European guideline evalu-
ation by the EUROASPIRE IV Study Group showed com-
parable secondary prevention rates at a median follow-up
time of 16 months after myocardial infarction: 94% an-
tiplatelets, 86% statins, 83% beta-blockers and 75% ACE
inhibitors/AT2 antagonists [27]. Another study from the
Netherlands evaluated secondary prevention during long-
term follow-up with usage of a similar patient linkage sys-
tem containing drug-dispensing records from community
pharmacies and hospitalised patients and showed an im-
provement in medication compliance over time (from 1999
till 2007) [28]. When comparing these results with the cur-
rent study, an additional improvement in medication adher-
ence over time can be observed, suggesting an increased
focus on adequate medication prescription after AMI. Ap-
proximately half of the currently studied patients do not
receive all five indicated drugs one year after AMI. The
measured suboptimal adherence of all five indicated drugs
is partly physician driven (the drugs are not prescribed,
whether or not on purpose) and can be partly patient driven
(the patient does not want the medication or is intolerant) [4,
18, 29]. In the guidelines of the European Society of Car-
diology, American Heart Association and American Col-
lege of Cardiology, beta-blocker and ACE inhibitor/AT2
antagonist use is indicated for patients with left ventricu-
lar dysfunction (Class 1, level A) and recommended if not
contra-indicated in the remaining group [4, 18, 29]. A com-
bined measurement of the five indicated drugs might have
its limitations as a quality indicator and therefore requests
careful interpretation. Comparison per type of medication
poses a more robust indicator for the assessment of quality
of care.
Future implications
National claims data offer a range of possibilities for au-
tomated and nationwide quality assessments without addi-
tional work for professionals, resulting in more time for
actual patient care. Furthermore, national claims data serve
as an opportunity in the evaluation of the patient’s chain
of care. Future research should focus on the development
of additional quality indicators and on the connection be-
tween currently available databases, such as primary care
databases to assess primary care follow-up, or nursery care
databases to assess functional status. In the Netherlands,
claims data serve as an additional measurement, alongside
the National Heart Registry (NHR) [30]. The NHR could
function as a national clinical database with more detailed
clinical information. National claims data could be used to
check the number in the clinical databases. In the long run,
when the field of cardiac professionals is ready, cost effec-
tive analysis is possible. A development that can already
be seen in the field of surgery, with the Dutch Institute
for Clinical Auditing (DICA) and the registration of claims
data [31]. All in all, this depends on new laws concerning
privacy and the will of politicians, hospitals and clinical
professionals.
Limitations
Some limitations should be addressed. Firstly, differences
in adherence between local and national databases may also
be caused by different adherence measuring methods; na-
tional databases are based on pharmacy fulfilment prescrip-
tion and local databases are based on self-reporting of the
patient, deducted from a chart review. This discrepancy be-
tween providing and fulfilment of the prescription is not
studied and therefore a small difference between the two
registries is in accordance with clinical practice and doesn’t
relate to data quality. Secondly, patients were lost to follow-
up in the validation registry. Reasons were a physician-
or patient-driven conservative approach because of the pa-
tient’s terminal disease or high age. Patients who were lost
to follow-up may be the patients that used less medication
and therefore could probably cause a selection bias of the
validation registry.
Conclusion
Nationwide routinely collected medical claims data in pa-
tients with AMI are accurate. This offers an opportunity for
use in quality assessments of cardiac care.
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